{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:53:30Z","timestamp":1784159610405,"version":"3.55.0"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Lumateperone (ITI-007) is a tosylate salt with binding affinities to receptors implicated in\nthe therapeutic actions of antipsychotic medications, including the serotonin 5HT2A receptors, dopamine\nD2 and D1 receptors and the serotonin transporter. It has a unique mechanism of action because it\nsimultaneously modulates serotonin, dopamine, and glutamate neurotransmission, implicated in serious\nmental illness. It can be considered a multi-target-directed ligand and a multifunctional modulator\nof serotoninergic system with possible precognitive, antipsychotic, antidepressant and anxiolytic properties.\nLumateperone has been investigated as a novel agent for the treatment of schizophrenia, but it\nrepresents a new potential option for other psychiatric and neurological diseases, such as behavioural\nsymptoms of dementia or Alzheimer\u2019s disease, sleep disturbances, bipolar depression. Besides, it has\ndemonstrated a favourable safety profile without significant extrapyramidal side effects, hyperprolactinemia\nor changes in cardiometabolic or endocrine factors versus placebo. Additional studies are warranted\nto confirm and examine the benefit of lumateperone and possible therapeutic targets. This paper\nis a comprehensive and thorough summary of the most important findings and potential future role of\nthis particular compound in personalized treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527319666200601145653","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T19:44:57Z","timestamp":1591040697000},"page":"243-247","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-8162","authenticated-orcid":true,"given":"Marianna","family":"Mazza","sequence":"first","affiliation":[{"name":"Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Marano","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianandrea","family":"Traversi","sequence":"additional","affiliation":[{"name":"Department of Science, University of Rome \u201cRoma Tre\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sani","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Janiri","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","volume":"232","author":"Snyder G.L.","year":"2015","unstructured":"Snyder G.L.; Vanover K.E.; Zhu H.; Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 2015,232(3),605-621","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","volume":"44","author":"Vanover K.E.","year":"2019","unstructured":"Vanover K.E.; Davis R.E.; Zhou Y.; Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology 2019,44(3),598-605","journal-title":"Neuropsychopharmacology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1871527317666181105101756","volume":"18","author":"Ibarra A.","year":"2019","unstructured":"Ibarra A.; Mendieta-Arbes\u00fa E.; Suarez-Meade P.; Motor recovery after chronic spinal cord transection in rats: a proof-of-concept study evaluating a combined strategy. CNS Neurol Disord Drug Targets 2019,18(1),52-62","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=4","author":"Raj K.","year":"2019","unstructured":"Raj K.; Chawla P.; Singh S.; Neurological disorders associated to long term tramadol utilization: pathological mechanisms and future perspective. CNS Neurol Disord Drug Targets epub ahead of print2019","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1871527318666181128144343","volume":"18","author":"Guzm\u00e1n D.C.","year":"2019","unstructured":"Guzm\u00e1n D.C.; Brizuela N.O.; Herrera M.O.; Cytarabine and ferric carboxymaltose (Fe+3) increase oxidative damage and alter serotonergic metabolism in brain. CNS Neurol Disord Drug Targets 2019,18(2),149-155","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/1871527317666181105111157","volume":"18","author":"Miri A.L.","year":"2019","unstructured":"Miri A.L.; Hosni A.P.; Gomes J.C.; Study of the effects of L-tryptophane nanoparticles on motor behavior in Alzheimer\u2019s experimental models. CNS Neurol Disord Drug Targets 2019,18(1),44-51","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/1871527317666180420150249","volume":"17","author":"de Oliveira D.R.","year":"2018","unstructured":"de Oliveira D.R.; da Silva D.M.; Florentino I.F.; Monoamine involvement in the antidepressant-like effect of \u03b2-caryophyllene. CNS Neurol Disord Drug Targets 2018,17(4),309-320","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/1871527317666180627103337","volume":"17","author":"Sahlholm K.","year":"2018","unstructured":"Sahlholm K.; Valle-Leon M.; Taura J.; Fernandez-Duenas V.; Ciruela F.; Effects of the dopamine stabilizer, pridopidine, on basal and phencyclidine-induced locomotion: role of dopamine D2 and sigma-1 receptors. CNS Neurol Disord Drug Targets 2018,17(7),522-527","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2174\/1871527318666190703103709","volume":"18","author":"Seyedi M.","year":"2019","unstructured":"Seyedi M.; Gholami F.; Samadi M.; The effect of vitamin D3 supplementation on serum BDNF, dopamine, and serotonin in children with attention-deficit\/hyperactivity disorder. CNS Neurol Disord Drug Targets 2019,18(6),496-501","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2174\/1871527317666180720163221","volume":"17","author":"Ormstad H.","year":"2018","unstructured":"Ormstad H.; Bryn V.; Verkerk R.; Serum tryptophan, tryptophan catabolites and brain-derived neurotrophic factor in subgroups of youngsters with autism spectrum disorders. CNS Neurol Disord Drug Targets 2018,17(8),626-639","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00213-015-3922-1","volume":"232","author":"Davis R.E.","year":"2015","unstructured":"Davis R.E.; Vanover K.E.; Zhou Y.; ITI-007 demonstrates brain occupancy at serotonin 5-HTA and dopamine D receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl) 2015,232(15),2863-2872","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","volume":"79","author":"Lieberman J.A.","year":"2016","unstructured":"Lieberman J.A.; Davis R.E.; Correll C.U.; ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry 2016,79(12),952-961","journal-title":"Biol Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.euroneuro.2019.07.001","volume":"29","author":"Corponi F.","year":"2019","unstructured":"Corponi F.; Fabbri C.; Bitter I.; Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol 2019,29(9),1061-1062","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S109285291900124X","volume":"24","author":"Krogmann A.","year":"2019","unstructured":"Krogmann A.; Peters L.; von Hardenberg L.; B\u00f6deker K.; N\u00f6hles V.B.; Correll C.U.; Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr 2019,24(S1),38-69","journal-title":"CNS Spectr"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/13543784.2017.1323870","volume":"26","author":"Wang S.M.","year":"2017","unstructured":"Wang S.M.; Han C.; Lee S.J.; Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opin Investig Drugs 2017,26(6),687-698","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2174\/1871527317666180828120256","volume":"17","author":"Mazza M.","year":"2018","unstructured":"Mazza M.; Marano G.; Traversi G.; Carocci V.; Romano B.; Janiri L.; Cariprazine in bipolar depression and mania: state of the art. CNS Neurol Disord Drug Targets 2018,17(10),723-727","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852916000729","volume":"21","author":"Citrome L.","year":"2016","unstructured":"Citrome L.; Emerging pharmacological therapies in schizophrenia: what\u2019s new, what\u2019s different, what\u2019s next? CNS Spectr 2016,21(S1),1-12","journal-title":"CNS Spectr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","volume":"16","author":"Davis R.E.","year":"2016","unstructured":"Davis R.E.; Correll C.U.; ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother 2016,16(6),601-614","journal-title":"Expert Rev Neurother"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.4379","author":"Correll C.U.","year":"2020","unstructured":"Correll C.U.; Davis R.E.; Weingart M.; Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry Epub ahead of print2020","journal-title":"JAMA Psychiatry"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","volume":"80","author":"Blair H.A.","year":"2020","unstructured":"Blair H.A.; Lumateperone: First Approval. Drugs 2020,80(4),417-423","journal-title":"Drugs"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","volume":"29","author":"Corponi F.","year":"2019","unstructured":"Corponi F.; Fabbri C.; Bitter I.; Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol 2019,29(9),971-985","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=22","first-page":"1","volume":"30","author":"Vyas P.","year":"2019","unstructured":"Vyas P.; Hwang B.J.; Brasic J.R.; An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother 2019,30,1-7","journal-title":"Expert Opin Pharmacother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.2174\/1381612819666131216115417","volume":"20","author":"Snyder G.L.","year":"2014","unstructured":"Snyder G.L.; Vanover K.E.; Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment. Curr Pharm Des 2014,20(31),5093-5103","journal-title":"Curr Pharm Des"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2017.1307340","volume":"18","author":"Porsteinsson A.P.","year":"2017","unstructured":"Porsteinsson A.P.; Antonsdottir I.M.; An update on the advancements in the treatment of agitation in Alzheimer\u2019s disease. Expert Opin Pharmacother 2017,18(6),611-620","journal-title":"Expert Opin Pharmacother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3389\/fphar.2019.01465","volume":"10","author":"Calsolaro V.","year":"2019","unstructured":"Calsolaro V.; Antognoli R.; Okoye C.; Monzani F.; The use of antipsychotic drugs for treating behavioral symptoms in Alzheimer\u2019s disease. Front Pharmacol 2019,10,1465","journal-title":"Front Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40266-019-00668-7","volume":"36","author":"Ahmed M.","year":"2019","unstructured":"Ahmed M.; Malik M.; Teselink J.; Lanct\u00f4t K.L.; Herrmann N.; Current agents in development for treating behavioral and psychological symptoms associated with dementia. Drugs Aging 2019,36(7),589-605","journal-title":"Drugs Aging"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2174\/0929867324666170529122802","volume":"25","author":"Jankowska A.","year":"2018","unstructured":"Jankowska A.; Wesolowska A.; Pawlowski M.; Chlon-Rzepa G.; Multi-target-directed ligands affecting serotonergic neurotransmission for Alzheimer\u2019s disease therapy: advances in chemical and biological research. Curr Med Chem 2018,25(17),2045-2067","journal-title":"Curr Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1517\/13543784.2015.987340","volume":"24","author":"Zisapel N.","year":"2015","unstructured":"Zisapel N.; Current phase II investigational therapies for insomnia. Expert Opin Investig Drugs 2015,24(3),401-411","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1021\/jm401958n","volume":"57","author":"Li P.","year":"2014","unstructured":"Li P.; Zhang Q.; Robichaud A.J.; Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J Med Chem 2014,57(6),2670-2682","journal-title":"J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1358\/dot.2018.54.12.2899443","volume":"54","author":"Kumar B.","year":"2018","unstructured":"Kumar B.; Kuhad A.; Kuhad A.; Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today (Barc) 2018,54(12),713-719","journal-title":"Drugs Today (Barc)"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.4265","author":"Kantrowitz J.T.","year":"2020","unstructured":"Kantrowitz J.T.; The potential role of lumateperone-something borrowed? something new? JAMA Psychiatry [Epub ahead of print]2020","journal-title":"JAMA Psychiatry"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/182394\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/182394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T20:17:35Z","timestamp":1614457055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182394\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319666200601145653","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}